FBR Capital analyst Vernon Bernardino reiterated a Market Perform rating and $192 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA

PBC Committee Opens The Door to $2.2B Opportunity For Intercept Pharma (ICPT) - WedbushApril 6, 2016 7:50 AM Baird Maintains Bullish View on Intercept Pharmaceuticals (ICPT) Following Positive Briefing DocsApril 5, 2016 10:32 AM Intercept Pharma (ICPT) Briefing Docs Raise New Questions, But All Appear Addressable - LeerinkApril 5, 2016 9:33 AM Wells Fargo Upgrades Intercept Pharmaceuticals (ICPT) to OutperformApril 5, 2016 9:02 AM Intercept Pharma (ICPT) FDA Briefing Documents PostedApril 5, 2016 8:01 AM